Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics (BCAX) went public on September 12, 2024. The company last reported earnings on November 10, 2025, which saw BCAX shares decline by 4.9%, but the stock has since increased by 19.1%. In January 2026, Citizens initiated coverage with a "Market Outperform" recommendation, and H.C. Wainwright and BTIG reiterated "Buy" ratings. The consensus among analysts is a "Moderate Buy" rating, with an average one-year price target of $31.05. Bicara Therapeutics announced the selection of 1500 mg of ficerafusp alfa as the optimal dose for its Phase 3 study in January 2026. Over the past three months, insiders have sold $1,784,142.00 of company stock. As of February 5, 2026, the share price was $15.12, a 20.00% increase from February 6, 2025, with a 52-week range of $7.80 to $19.71.

As a clinical-stage biopharmaceutical company, Bicara Therapeutics, Inc. does not have commercialized products subject to traditional demand seasonality. Its primary focus is on research and development, so demand seasonality is not applicable at this stage.

Bicara Therapeutics, Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, operating in the Health Technology sector, specifically in Biotechnology and Pharmaceuticals with a focus on Drug Discovery. Their lead product candidate, ficerafusp alfa (BCA101), is a dual-action antibody in clinical development for multiple solid tumor cancer types, including head and neck squamous cell carcinoma. The company aims to translate scientific discoveries into life-changing therapies by modulating the tumor microenvironment and enhancing anti-tumor immune responses.

Bicara Therapeutics, Inc. is headquartered in Boston, Massachusetts, and states it serves "Worldwide," though specific details regarding its global operational locations or market reach beyond its headquarters are not extensively detailed.

Bicara Therapeutics maintains a positive brand reputation due to its innovative approach to cancer treatment and promising pipeline. Analyst sentiment is positive, with a "Moderate Buy" rating and projected upside potential. The company's focus on transformative therapies and commitment to improving lives contributes to a strong image. Recent clinical progress reinforces its reputation as a forward-thinking biopharmaceutical company, and increased search interest indicates growing attention.

Bicara Therapeutics Inc. has 211 institutional owners and shareholders holding 52,444,106 shares, with major shareholders including Ra Capital Management, L.p., Siren, L.L.C., and Vestal Point Capital, LP. Ra Capital Management holds 12.70% ownership, Siren, L.L.C. holds 9.52%, and Vestal Point Capital holds 9.31%. Current insider ownership stands at 15.50% of the stock.